Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch

Ligand Pharma (LGND) Reports Expanded License Agreement with CURx Pharma

September 9, 2014 8:37 AM EDT

Ligand Pharma (Nasdaq: LGND) has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligands Captisol-enabled Lamotrigine program. Under the terms of the expanded license, Ligand will be eligible to receive $22 million in potential milestone payments,... More